GlassScriptPhysician profile
Kirt Mckinlay
NPI 1902843089
$1,787.10
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $713 · 2020: $539 · 2021: $535.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $196.30 | 2019-2021 | |
| Amgen INC. | $186.74 | 2019-2021 | |
| Astellas Pharma US INC | $180.91 | 2019-2021 | |
| Novo Nordisk INC | $163.36 | 2019-2021 | |
| Pfizer INC. | $141.99 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.16 | 2019-2021 | |
| Allergan, INC. | $101.68 | 2019-2020 | |
| Abbvie INC. | $101.38 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $87.41 | 2019-2021 | |
| Glaxosmithkline, LLC. | $66.25 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $61.47 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $53.73 | 2021 | |
| Nestle Healthcare Nutrition INC. | $37.47 | 2020-2021 | |
| Amarin Pharma, INC. | $36.79 | 2020 | |
| Merck Sharp & Dohme LLC | $36.03 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $32.63 | 2019-2021 | |
| Genentech USA, INC. | $28.38 | 2019-2020 | |
| Therapeuticsmd, INC. | $26.17 | 2019-2021 | |
| Eisai INC. | $22.64 | 2021 | |
| Arbor Pharmaceuticals, INC. | $16.47 | 2021 | |
| Abbott Laboratories | $15.39 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.72 | 2021 | |
| Sunovion Pharmaceuticals INC. | $12.64 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.37 | 2021 | |
| Boston Scientific Corporation | $11.65 | 2019 | |
| Shire North American Group INC | $11.37 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirt Mckinlay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.